Overview

Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers

Status:
NOT_YET_RECRUITING

Trial end date:
2025-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the pharmacokinetics and safety of HDP023 and coadministration of Teneligliptin and Empagliflozin in healthy adult volunteers

Phase:

PHASE1

Details

Lead Sponsor:

Handok Inc.

Treatments:

3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine
empagliflozin